Apellis shares are trading higher after the company said events of retinal vasculitis in treatment with SYFOVRE were rare, with an estimated real-world rate of 0.01% per injection.
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals has announced that events of retinal vasculitis in treatment with SYFOVRE are rare, with an estimated real-world rate of 0.01% per injection. This news has led to an increase in the company's share price.
August 23, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals' shares are trading higher following the company's announcement about the rarity of retinal vasculitis in treatment with SYFOVRE.
The announcement from Apellis Pharmaceuticals about the rarity of retinal vasculitis in treatment with SYFOVRE is positive news for the company. This has led to an increase in the company's share price, indicating investor confidence in the product and the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100